---
title: "EBOS Updates Market on Lapse of Performance Rights"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/274735098.md"
description: "EBOS Group Limited announced that 6,465 performance rights have lapsed, reducing the total to 1,444,595 currently outstanding. This adjustment decreases potential future dilution from equity-based incentives and clarifies the company's long-term incentive arrangements. The latest analyst rating for EBOS (AU:EBO) is a Hold with a price target of A$26.00. EBOS is a healthcare and pharmaceutical distributor in New Zealand and Australia, with a market cap of A$4.55B."
datetime: "2026-02-04T00:57:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274735098.md)
  - [en](https://longbridge.com/en/news/274735098.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274735098.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/274735098.md) | [繁體中文](https://longbridge.com/zh-HK/news/274735098.md)


# EBOS Updates Market on Lapse of Performance Rights

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

EBOS Group Limited ( (AU:EBO) ) has issued an announcement.

EBOS Group Limited has reported that 6,465 performance rights have lapsed, leaving 1,444,595 performance rights currently on issue. The adjustment marginally reduces the potential future dilution from equity-based incentives and provides investors with an updated picture of the company’s outstanding performance rights, clarifying the scale of its long-term incentive arrangements for key personnel.

The most recent analyst rating on (AU:EBO) stock is a Hold with a A$26.00 price target. To see the full list of analyst forecasts on EBOS Group Limited stock, see the AU:EBO Stock Forecast page.

**More about EBOS Group Limited**

EBOS Group Limited is a trans-Tasman healthcare and pharmaceutical products distributor and marketer, serving pharmacies, hospitals, medical professionals and other healthcare providers in New Zealand and Australia.

**Average Trading Volume:** 131,055

**Technical Sentiment Signal:** Sell

**Current Market Cap:** A$4.55B

For an in-depth examination of EBO stock, go to TipRanks’ Overview page.

### 相关股票

- [EBOS Group Limited (EBO.AU)](https://longbridge.com/zh-CN/quote/EBO.AU.md)

## 相关资讯与研究

- [Citi Sticks to Its Hold Rating for EBOS Group Limited (EBO)](https://longbridge.com/zh-CN/news/273758993.md)
- [Macquarie Reaffirms Their Buy Rating on EBOS Group Limited (EBO)](https://longbridge.com/zh-CN/news/276987307.md)
- [New Zealand Energy Corp. Announces Strong Initial Production Results from Ngaere-2 Well | NZERF Stock News](https://longbridge.com/zh-CN/news/281020759.md)
- [11:35 ETMediaspace Health Launches to Deliver Innovative Media Strategies for Agencies, Pharma and Healthcare Brands](https://longbridge.com/zh-CN/news/281213630.md)
- [Mercury NZ Issues New Shares Under Dividend Reinvestment Plan](https://longbridge.com/zh-CN/news/281310208.md)